Swedish Orphan Biovitrum
| Type | Public |
|---|---|
| Nasdaq Stockholm: SOBI | |
| Industry | Pharmaceutical |
| Headquarters | Stockholm, Sweden |
| Key people | |
| Products | Treatments in the areas of haematology, immunology and specialty care |
| Revenue | SEK 28.2 bn (2025) |
| SEK 22.0 bn (2025) | |
| Total assets | SEK 67.4 bn (2025) |
| Total equity | SEK 37.7 bn (2025) |
Number of employees | ~1,900 (2025) |
| Parent | Investor AB (34.7%) |
| Website | sobi.com |
| Footnotes Sobi Annual and Sustainability Reports | |
Sobi - Swedish Orphan Biovitrum AB is an international biopharmaceutical company focused on rare diseases. The company develops, commercializes, and delivers therapies in the fields of haematology, immunology and specialty care. Headquartered in Stockholm, Sweden, with major hubs in Basel, Switzerland, and Waltham, USA.
Sobi has a global presence in approximately 30 countries and provides medicines to patients in many more around world. The company develops treatments for patients living with complex and chronic rare conditions and maintains a pipeline of development and lifecycle management programs focused on advancing innovative therapies for diseases with significant unmet medical needs.